ArticleMolecules (Basel, Switzerland)2025
A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring.
Valentina D'Atri, Fabrizio Corrado, François Versace, Susana Alves Saldanha, Thomas Mercier, Monia Guidi, Paul Thoueille, Sylvain Blanchon, Angela Koutsokera, Michael Vogeser and 8 more
Abstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Valentina D'AtriService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-2601-7092 Fabrizio CorradoService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
François VersaceService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-7262-7617 Susana Alves SaldanhaService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Thomas MercierService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0003-1921-4837 Monia GuidiService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-6419-9317 Paul ThoueilleService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-2305-4277 Sylvain BlanchonPediatric Pneumology and Cystic Fibrosis Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0003-0284-9705 Angela KoutsokeraAdult Cystic Fibrosis and CFTR-Related Disorders Center, Division of Pulmonology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0003-1227-1679 Michael VogeserInstitute of Laboratory Medicine, LMU University Hospital, 81377 Munich, Germany.
Catia MarzoliniService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-2312-7050 François GirardinService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-0842-927X Georgia MitropoulouAdult Cystic Fibrosis and CFTR-Related Disorders Center, Division of Pulmonology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-8864-2467 Zisis BalmpouzisAdult Cystic Fibrosis and CFTR-Related Disorders Center, Division of Pulmonology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Isabelle RochatPediatric Pneumology and Cystic Fibrosis Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0003-2818-8757 Alain SautyAdult Cystic Fibrosis and CFTR-Related Disorders Center, Division of Pulmonology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Laurent Arthur DecosterdService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-9840-1325 Eva ChoongService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0001-6776-4978 Funding
Cystic Fibrosis Switzerland and the Swiss Working Group for Cystic Fibrosis (SWGCF) 2022SNF 32003B_179273SNF 324730_192449
6 · The paper itselfAbstract
Cystic fibrosis (CF) is a life-threatening disorder caused by mutations in the CFTR gene, leading to defective chloride ion transport and thickened mucus in the respiratory and gastrointestinal systems. CFTR modulators, including ivacaftor, lumacaftor, tezacaftor, and elexacaftor, have improved patient outcomes, but interindividual pharmacokinetic variability and potential drug-drug interactions require therapeutic drug monitoring (TDM) for optimal efficacy and safety. In this context, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the simultaneous quantification of CFTR modulators and their major active metabolites in human plasma to support pharmacokinetic studies and routine TDM. The multiplex LC-MS/MS assay was established using plasma protein precipitation, followed by chromatographic separation on an Xselect HSS T3 (Waters
Indexed as
Cystic FibrosisDrug MonitoringTandem Mass SpectrometryAminophenolsAminopyridinesBenzodioxolesChromatography, LiquidCystic Fibrosis Transmembrane Conductance RegulatorHumansIndolesQuinolonesReproducibility of ResultsAminophenolsAminopyridinesBenzodioxolesCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorIndolesivacaftorlumacaftorQuinolonestezacaftorCFTR modulatorscystic fibrosisLC-MS/MSmethod developmentpharmacokineticsprecision medicinequantificationtherapeutic drug monitoringvalidation
Identifiers
PMID40363673
PMCPMC12073025
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390